National Pension Service Increases Stake in United Therapeutics Corporation $UTHR

National Pension Service grew its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 17.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 47,893 shares of the biotechnology company’s stock after buying an additional 7,249 shares during the quarter. National Pension Service’s holdings in United Therapeutics were worth $23,336,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AE Wealth Management LLC boosted its stake in shares of United Therapeutics by 396.3% in the 3rd quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock valued at $1,798,000 after buying an additional 3,424 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of United Therapeutics by 194.7% in the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after buying an additional 2,975 shares during the period. Optimize Financial Inc purchased a new position in shares of United Therapeutics in the 3rd quarter valued at about $444,000. Tobam boosted its stake in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after buying an additional 4,953 shares during the period. Finally, Leuthold Group LLC boosted its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after buying an additional 3,126 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on UTHR shares. Raymond James Financial started coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price objective for the company. Cantor Fitzgerald lifted their price objective on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Morgan Stanley set a $516.00 target price on United Therapeutics in a research note on Thursday, May 7th. Finally, TD Cowen restated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $619.42.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $565.63, for a total transaction of $5,656,300.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $10,676,831.88. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $562.82, for a total value of $4,671,406.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $25,423,705.04. This trade represents a 15.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 601,473 shares of company stock worth $337,090,644 over the last 90 days. 8.60% of the stock is owned by insiders.

United Therapeutics News Summary

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics is still drawing support from bullish analyst coverage, including recent higher price targets and buy/overweight ratings, which suggests Wall Street remains constructive on the long-term outlook.
• Positive Sentiment: The company continues to highlight clinical and business-development catalysts, including its PHINDER screening study, xenokidney/EXTEND trial progress, and a planned presentation at the Jefferies Global Healthcare Conference, all of which help keep the growth story visible to investors. Article Title Article Title
• Neutral Sentiment: A separate article referenced United Therapeutics in a broader mid-cap stock discussion, but it did not appear to contain company-specific new information likely to move the stock.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares and CFO James Edgemond sold 10,000 shares this week. Multiple insider sales can weigh on sentiment, especially when they come soon after a disappointing earnings report. Article Title Article Title
• Negative Sentiment: The company’s most recent quarterly results missed estimates on both EPS and revenue, leaving investors with an ongoing fundamental overhang despite strong profitability metrics.

United Therapeutics Price Performance

UTHR stock opened at $556.82 on Monday. The business has a 50 day moving average price of $566.51 and a 200 day moving average price of $516.27. The stock has a market cap of $23.64 billion, a price-to-earnings ratio of 20.55, a PEG ratio of 1.81 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.63 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 26.92 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.